Details of the Drug

General Information of Drug (ID: DM5UGDK)

Drug Name
Mephenytoin
Synonyms
Epiazin; Epilan; Fenantoin; Insulton; Mefenetoin; Mefenitoina; Mephenetoinum; Mephentoin; Mephenytoine; Mephenytoinum; Mesantoin; Mesdontoin; Mesontoin; Methoin; Methylphenetoin; Metydan; Phenantoin; Phenylethylmethylhydantoin; Sacerno; Sedantional; Sedantoin; Sedantoinal; Triantoin; Ydantoin; Methyl Phenetoin; Methyl hydantoin; MU2276000; Gerot-epilan; L-Mephenytoin; Mefenitoina [INN-Spanish]; Mephenytoin [USAN:INN]; Mephenytoine [INN-French]; Mephenytoinum [INN-Latin]; Mesantoin (TN); Phenetoin, Methyl;Mephenytoin (USP/INN); L-3-Methyl-5-ethyl-5-phenylhydantoin; (+-)-5-Ethyl-3-methyl-5-phenylhydantoin; (+-)-Mephenytoin; (-)-5-Ethyl-3-methyl-5-phenylhydantoin; 3-Ethylnirvanol; 3-Methyl-5, 5-ethylphenylhydantoin; 3-Methyl-5,5-ethylphenylhydantoin; 3-Methyl-5,5-phenylethylhydantoin; 3-Methyl-5-ethyl-5-phenylh; 3-Methyl-5-ethyl-5-phenylhydantoin; 5 Ethyl 3 Methyl 5 Phenylhydantoin; 5-Ethyl-3-methyl-5-phenyl-2,4(3H,5H)-imidazoledione; 5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione; 5-Ethyl-3-methyl-5-phenylhydantoin; 5-Ethyl-3-methyl-5-phenylimidazolidin-2,4-dione; 5-Ethyl-5-fenyl-3-methylhydantoin; 5-Ethyl-5-fenyl-3-methylhydantoin [Czech]; 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1]
Therapeutic Class
Anticonvulsants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 218.25
Logarithm of the Partition Coefficient (xlogp) 1.5
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 hours [3]
Vd
The volume of distribution (Vd) of drug is 1.4 L/kg []
Chemical Identifiers
Formula
C12H14N2O2
IUPAC Name
5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
Canonical SMILES
CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2
InChI
InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)
InChIKey
GMHKMTDVRCWUDX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4060
ChEBI ID
CHEBI:6757
CAS Number
50-12-4
DrugBank ID
DB00532
TTD ID
D07RGW
VARIDT ID
DR00839
INTEDE ID
DR1025
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A) TTZOVE0 SCN5A_HUMAN Blocker [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [6]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [7]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [8]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [5]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [11]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Biotransformations [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mephenytoin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Diazepam DM08E9O Moderate Increased metabolism of Mephenytoin caused by Diazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Mephenytoin caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Methsuximide DM6L5VO Moderate Increased metabolism of Mephenytoin caused by Methsuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Ethosuximide DMDZ9LT Moderate Increased metabolism of Mephenytoin caused by Ethosuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Tiagabine DMKSQG0 Moderate Increased metabolism of Mephenytoin caused by Tiagabine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Clonazepam DMTO13J Moderate Increased metabolism of Mephenytoin caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Carbamazepine DMZOLBI Moderate Increased metabolism of Mephenytoin caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Mephenytoin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [14]
Emapalumab DMZG5WL Moderate Altered metabolism of Mephenytoin due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [18]
Mitotane DMU1GX0 Minor Increased metabolism of Mephenytoin caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [19]
Siltuximab DMGEATB Moderate Altered metabolism of Mephenytoin due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [18]
Bepridil DM0RKS4 Moderate Increased metabolism of Mephenytoin caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [20]
Nifedipine DMSVOZT Moderate Increased metabolism of Mephenytoin caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [20]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [21]
Clorazepate DMC3JST Moderate Increased metabolism of Mephenytoin caused by Clorazepate mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [22]
Voriconazole DMAOL2S Moderate Decreased metabolism of Mephenytoin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [14]
Aminophylline DML2NIB Moderate Increased metabolism of Mephenytoin caused by Aminophylline mediated induction of CYP450 enzyme. Asthma [CA23] [23]
Clarithromycin DM4M1SG Moderate Increased metabolism of Mephenytoin caused by Clarithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [24]
Troleandomycin DMUZNIG Moderate Increased metabolism of Mephenytoin caused by Troleandomycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Mephenytoin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [25]
Alpelisib DMEXMYK Moderate Increased metabolism of Mephenytoin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Levomilnacipran DMV26S8 Moderate Antagonize the effect of Mephenytoin when combined with Levomilnacipran. Chronic pain [MG30] [27]
Anisindione DM2C48U Moderate Increased metabolism of Mephenytoin caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [28]
Tubocurarine DMBZIVP Moderate Increased metabolism of Mephenytoin caused by Tubocurarine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [14]
Oxtriphylline DMLHSE3 Moderate Increased metabolism of Mephenytoin caused by Oxtriphylline mediated induction of CYP450 enzyme. Cough [MD12] [29]
Mycophenolic acid DMRBMAU Minor Increased plasma concentration of Mephenytoin and Mycophenolic acid due to competitive binding of plasma proteins. Crohn disease [DD70] [30]
Mifepristone DMGZQEF Moderate Decreased metabolism of Mephenytoin caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [31]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Mephenytoin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [32]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Mephenytoin and Ethanol. Cystitis [GC00] [14]
MK-8228 DMOB58Q Moderate Increased metabolism of Mephenytoin caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [33]
Vilazodone DM4LECQ Moderate Antagonize the effect of Mephenytoin when combined with Vilazodone. Depression [6A70-6A7Z] [27]
Paroxetine DM5PVQE Moderate Antagonize the effect of Mephenytoin when combined with Paroxetine. Depression [6A70-6A7Z] [27]
Vortioxetine DM6F1PU Moderate Antagonize the effect of Mephenytoin when combined with Vortioxetine. Depression [6A70-6A7Z] [27]
Milnacipran DMBFE74 Moderate Antagonize the effect of Mephenytoin when combined with Milnacipran. Depression [6A70-6A7Z] [27]
Desvenlafaxine DMHD4PE Moderate Antagonize the effect of Mephenytoin when combined with Desvenlafaxine. Depression [6A70-6A7Z] [27]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Mephenytoin and Esketamine. Depression [6A70-6A7Z] [14]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Cannabidiol. Epileptic encephalopathy [8A62] [34]
Nicardipine DMCDYW7 Moderate Increased metabolism of Mephenytoin caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [20]
Itraconazole DMCR1MV Moderate Increased metabolism of Mephenytoin caused by Itraconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Miconazole DMPMYE8 Moderate Decreased metabolism of Mephenytoin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [35]
Ketoconazole DMPZI3Q Moderate Increased metabolism of Mephenytoin caused by Ketoconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Mephenytoin caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [14]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [36]
Etravirine DMGV8QU Moderate Decreased metabolism of Mephenytoin caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Mephenytoin caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [14]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Mephenytoin and Mipomersen. Hyper-lipoproteinaemia [5C80] [38]
Clofibrate DMPC1J7 Minor Increased plasma concentration of Mephenytoin and Clofibrate due to competitive binding of plasma proteins. Hyper-lipoproteinaemia [5C80] [14]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Mephenytoin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [39]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Mephenytoin and BMS-201038. Hyper-lipoproteinaemia [5C80] [40]
Levamlodipine DM92S6N Moderate Increased metabolism of Mephenytoin caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [20]
Verapamil DMA7PEW Moderate Increased metabolism of Mephenytoin caused by Verapamil mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [41]
Felodipine DMOSW35 Moderate Increased metabolism of Mephenytoin caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [42]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Mephenytoin caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [43]
Flurazepam DMAL4G0 Moderate Increased metabolism of Mephenytoin caused by Flurazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [13]
Triazolam DMETYK5 Moderate Increased metabolism of Mephenytoin caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [13]
Quazepam DMY4D87 Moderate Increased metabolism of Mephenytoin caused by Quazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [13]
Estazolam DMZGXUM Moderate Increased metabolism of Mephenytoin caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [13]
Remimazolam DMLVSYX Moderate Increased metabolism of Mephenytoin caused by Remimazolam mediated induction of CYP450 enzyme. Labour/delivery anaesthesia complication [JB0C] [22]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Methotrexate. Leukaemia [2A60-2B33] [34]
PF-06463922 DMKM7EW Moderate Increased metabolism of Mephenytoin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [14]
Chloroquine DMSI5CB Moderate Antagonize the effect of Mephenytoin when combined with Chloroquine. Malaria [1F40-1F45] [14]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Mephenytoin when combined with Hydroxychloroquine. Malaria [1F40-1F45] [14]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [44]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Idelalisib. Mature B-cell leukaemia [2A82] [45]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Clofarabine. Mature B-cell lymphoma [2A85] [46]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Mephenytoin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [34]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Mephenytoin and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [47]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Mephenytoin and Lasmiditan. Migraine [8A80] [48]
Midazolam DMXOELT Moderate Increased metabolism of Mephenytoin caused by Midazolam mediated induction of CYP450 enzyme. Mood/affect symptom [MB24] [13]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Mephenytoin and Thalidomide. Multiple myeloma [2A83] [49]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Mephenytoin and Ocrelizumab. Multiple sclerosis [8A40] [50]
Rifabutin DM1YBHK Moderate Increased metabolism of Mephenytoin caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [51]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Mephenytoin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [52]
Modafinil DMYILBE Moderate Decreased metabolism of Mephenytoin caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [14]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Mephenytoin and Dextropropoxyphene. Pain [MG30-MG3Z] [53]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Mephenytoin and Buprenorphine. Pain [MG30-MG3Z] [54]
Abametapir DM2RX0I Moderate Decreased metabolism of Mephenytoin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [55]
Esomeprazole DM7BN0X Minor Increased plasma concentrations of Mephenytoin and Esomeprazole due to competitive inhibition of the same metabolic pathway. Peptic ulcer [DA61] [56]
Prednisone DM2HG4X Moderate Increased metabolism of Mephenytoin caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [43]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Mephenytoin caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [43]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Mephenytoin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [57]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Mephenytoin due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [34]
Ixekizumab DMXW92T Moderate Altered metabolism of Mephenytoin due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [34]
Tocilizumab DM7J6OR Moderate Altered metabolism of Mephenytoin due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Canakinumab DM8HLO5 Moderate Altered metabolism of Mephenytoin due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Rilonacept DMGLUQS Moderate Altered metabolism of Mephenytoin due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Golimumab DMHZV7X Moderate Altered metabolism of Mephenytoin due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Dexamethasone DMMWZET Moderate Increased metabolism of Mephenytoin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [43]
Sarilumab DMOGNXY Moderate Altered metabolism of Mephenytoin due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Mephenytoin and Leflunomide. Rheumatoid arthritis [FA20] [39]
Methylprednisolone DM4BDON Moderate Increased metabolism of Mephenytoin caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [34]
Armodafinil DMGB035 Moderate Decreased metabolism of Mephenytoin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [14]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Mephenytoin caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Disulfiram DMCL2OK Moderate Decreased metabolism of Mephenytoin caused by Disulfiram mediated inhibition of CYP450 enzyme. Substance abuse [6C40] [58]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Mephenytoin and Naltrexone. Substance abuse [6C40] [59]
Warfarin DMJYCVW Moderate Increased metabolism of Mephenytoin caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [60]
Pipecuronium DM5F84A Moderate Increased metabolism of Mephenytoin caused by Pipecuronium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [14]
Doxacurium DMKE7L9 Moderate Increased metabolism of Mephenytoin caused by Doxacurium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [14]
Cisatracurium DMUZPJ5 Moderate Increased metabolism of Mephenytoin caused by Cisatracurium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [61]
Rocuronium DMY9BMK Moderate Increased metabolism of Mephenytoin caused by Rocuronium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [61]
Mycophenolate mofetil DMPQAGE Minor Increased plasma concentration of Mephenytoin and Mycophenolate mofetil due to competitive binding of plasma proteins. Transplant rejection [NE84] [30]
Canagliflozin DMFRM1I Moderate Increased metabolism of Mephenytoin caused by Canagliflozin mediated induction of UGT. Type 2 diabetes mellitus [5A11] [14]
Nitrofurantoin DM7PQIK Moderate Increased metabolism of Mephenytoin caused by Nitrofurantoin mediated induction of CYP450 enzyme. Urinary tract infection [GC08] [62]
Triamcinolone DM98IXF Moderate Increased metabolism of Mephenytoin caused by Triamcinolone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [43]
⏷ Show the Full List of 98 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7223).
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
5 Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther. 1993 Jan;264(1):89-94.
6 Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95.
7 Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis. 1996 Sep;17(9):2029-34.
8 Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
9 Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994 Feb 22;33(7):1743-52.
12 Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos. 2002 Dec;30(12):1311-9.
13 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
14 Cerner Multum, Inc. "Australian Product Information.".
15 Browne TR, Feldman RG, Buchanan RA, et al. "Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions." Neurology 33 (1983): 414-8. [PMID: 6403891]
16 Product Information. Gabitril (tiagabine). Abbott Pharmaceutical, Abbott Park, IL.
17 Gratz ES, Theodore WH, Newmark ME, Kupferberg HJ, Porter RJ, Qu Z "Effect of carbamazepine on phenytoin clearance in patients with complex partial seizures." Neurology 32 (1982): a223.
18 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
19 Product Information. Lysodren (mitotane). Bristol-Myers Squibb, Princeton, NJ.
20 Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
21 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
22 Murphy A, Wilbur K "Phenytoin-diazepam interaction." Ann Pharmacother 37 (2003): 659-63. [PMID: 12708941]
23 Crowley JJ, Cusack BJ, Jue SG, et al "Cigarette smoking and theophylline metabolism: effects of phenytoin." Clin Pharmacol Ther 42 (1987): 334-40. [PMID: 3621789]
24 Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L "Single dose phenytoin clearance during erythromycin treatment." Res Commun Chem Pathol Pharmacol 46 (1984): 207-17. [PMID: 6515115]
25 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
26 Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
27 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
28 Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (first of two parts)." N Engl J Med 285 (1971): 487-98. [PMID: 4397794]
29 Miller M, Cosgriff J, Kwong T, Morken DA "Influence of phenytoin on theophylline clearance." Clin Pharmacol Ther 35 (1984): 666-9. [PMID: 6713777]
30 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
31 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
32 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
33 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
34 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35 Rolan PE, Somogyi AA, Drew MJ, et al "Phenytoin intoxication during treatment with parenteral miconazole." Br Med J (Clin Res Ed) 287 (1983): 1760. [PMID: 6416579]
36 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
37 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
38 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
39 Canadian Pharmacists Association.
40 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
41 Hedman A, Angelin B, Arvidsson A, et al "Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans." Clin Pharmacol Ther 49 (1991): 256-62. [PMID: 2007320]
42 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
43 Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
44 Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
45 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
46 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
47 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
48 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
49 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
50 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
51 Abajo FJ "Phenytoin interaction with rifampicin." Br Med J 297 (1988): 1048. [PMID: 3142625]
52 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
53 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
54 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
55 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
56 Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
57 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
58 Brown CG, Kaminsky MJ, Feroli ER, Gurley HT "Delirium with phenytoin and disulfiram administration." Ann Emerg Med 12 (1983): 310-3. [PMID: 6625283]
59 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
60 Hansen JM, Siersboek-Nielsen K, Skovsted L "Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man." Clin Pharmacol Ther 12 (1971): 539-43. [PMID: 5567804]
61 Liberman BA, Norman P, Hardy BG "Pancuronium-phenytoin interaction: a case of decreased duration of neuromuscular blockade." Int J Clin Pharmacol Ther Toxicol 26 (1988): 371-4. [PMID: 3220609]
62 Heipertz R, Pilz H "Interaction of nitrofurantoin with diphenylhydantoin." J Neurol 218 (1978): 297-301. [PMID: 81279]